CN1617730A - 用于增强皮质类固醇传递的组合物和方法 - Google Patents

用于增强皮质类固醇传递的组合物和方法 Download PDF

Info

Publication number
CN1617730A
CN1617730A CNA028277236A CN02827723A CN1617730A CN 1617730 A CN1617730 A CN 1617730A CN A028277236 A CNA028277236 A CN A028277236A CN 02827723 A CN02827723 A CN 02827723A CN 1617730 A CN1617730 A CN 1617730A
Authority
CN
China
Prior art keywords
composition
corticosteroid
solvent
present
stearate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028277236A
Other languages
English (en)
Chinese (zh)
Inventor
E·H·甘斯
M·S·沃泽曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicis Pharmaceutical Corp
Original Assignee
Medicis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21893928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1617730(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medicis Pharmaceutical Corp filed Critical Medicis Pharmaceutical Corp
Publication of CN1617730A publication Critical patent/CN1617730A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C16/00—Erasable programmable read-only memories
    • G11C16/02—Erasable programmable read-only memories electrically programmable
    • G11C16/04—Erasable programmable read-only memories electrically programmable using variable threshold transistors, e.g. FAMOS
    • G11C16/0408—Erasable programmable read-only memories electrically programmable using variable threshold transistors, e.g. FAMOS comprising cells containing floating gate transistors
    • G11C16/0433—Erasable programmable read-only memories electrically programmable using variable threshold transistors, e.g. FAMOS comprising cells containing floating gate transistors comprising cells containing a single floating gate transistor and one or more separate select transistors
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C2216/00—Indexing scheme relating to G11C16/00 and subgroups, for features not directly covered by these groups
    • G11C2216/02—Structural aspects of erasable programmable read-only memories
    • G11C2216/10—Floating gate memory cells with a single polysilicon layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA028277236A 2001-12-21 2002-12-12 用于增强皮质类固醇传递的组合物和方法 Pending CN1617730A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/037,360 2001-12-21
US10/037,360 US6765001B2 (en) 2001-12-21 2001-12-21 Compositions and methods for enhancing corticosteroid delivery

Publications (1)

Publication Number Publication Date
CN1617730A true CN1617730A (zh) 2005-05-18

Family

ID=21893928

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028277236A Pending CN1617730A (zh) 2001-12-21 2002-12-12 用于增强皮质类固醇传递的组合物和方法

Country Status (9)

Country Link
US (8) US6765001B2 (https=)
EP (2) EP1465636A4 (https=)
JP (2) JP2005524614A (https=)
CN (1) CN1617730A (https=)
BR (1) BR0215254A (https=)
CA (1) CA2471041C (https=)
IL (1) IL162581A0 (https=)
MX (1) MXPA04006014A (https=)
WO (1) WO2003055445A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102988992A (zh) * 2011-09-13 2013-03-27 日东电工株式会社 用于增强酸性药物的透皮吸收的组合物和贴片制剂
CN104884043A (zh) * 2012-10-18 2015-09-02 米卡尔制药有限公司-H系列 局部类固醇组合物和方法

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630152B2 (en) * 1999-04-07 2003-10-07 Shen Wei (Usa), Inc. Aloe vera glove and manufacturing method
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
ES2532906T5 (es) 2002-10-25 2022-03-23 Foamix Pharmaceuticals Ltd Espuma cosmética y farmacéutica
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8119150B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7700076B2 (en) * 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US20050238672A1 (en) * 2004-04-27 2005-10-27 Nimni Marcel E Antifungal drug delivery
US7897587B2 (en) 2004-09-03 2011-03-01 Nycomed Us Inc. Topical dermatological formulations and use thereof
AU2006298442A1 (en) 2005-05-09 2007-04-12 Foamix Ltd. Saccharide foamable compositions
CA2607608A1 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
PL1906916T3 (pl) * 2005-05-10 2009-02-27 Alcon Inc Zawiesina do oczu obejmująca lek okulistyczny, poloksaminę i glikolowy środek regulujący toniczność, zastosowanie wymienionej kompozycji do wytwarzania leku do leczenia zaburzeń wzroku
WO2007046315A1 (ja) * 2005-10-17 2007-04-26 Nisshin Kyorin Pharmaceutical Co., Ltd. 皮膚外用剤
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US20100130460A1 (en) * 2005-12-09 2010-05-27 Nycomed Us Inc. Topical glucocorticosteroid formulations
US20070179121A1 (en) * 2006-02-02 2007-08-02 Plott R T Method of treating pediatric patients with corticosteroids
EP1998742A2 (en) * 2006-03-08 2008-12-10 Nuviance, INC. Transdermal drug delivery compositions and topical compositions for application on the skin
FR2898499B1 (fr) * 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
US8413435B2 (en) * 2006-06-13 2013-04-09 Wescast Industries, Inc. Exhaust manifolds including heat shield assemblies
PT2494959E (pt) * 2006-07-05 2015-02-20 Foamix Pharmaceuticals Ltd Veículo formador de espuma de ácido dicarboxílico e suas composições farmacêuticas
GB2443161B (en) * 2006-10-28 2011-03-23 Nupharm Lab Ltd Clobetasol spray
GB2443162B (en) * 2006-10-28 2011-02-09 Nupharm Lab Ltd Betamethasone spray
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
WO2008070538A2 (en) 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
US20080152592A1 (en) * 2006-12-21 2008-06-26 Bayer Healthcare Llc Method of therapeutic drug monitoring
JP2010514789A (ja) * 2006-12-27 2010-05-06 アベール ファーマシューティカルズ インコーポレイテッド 副腎皮質ステロイド投与のための経皮的方法及びパッチ
WO2008115224A2 (en) * 2007-03-20 2008-09-25 Bayer Healthcare Llc Method of analyzing an analyte
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US20090298803A1 (en) * 2008-05-28 2009-12-03 Glenmark Generics Ltd. Pharmaceutical composition comprising fluocinonide
MX379265B (es) * 2008-06-26 2025-03-11 Anterios Inc Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel.
TW201035054A (en) * 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
AR077490A1 (es) * 2009-07-21 2011-08-31 Novartis Ag Composiciones farmaceuticas topicas para el tratamiento de una condicion hiperproliferativa de la piel
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
ES2637447T3 (es) 2009-08-31 2017-10-13 Dr. Reddy's Laboratories Ltd. Formulaciones tópicas que contienen un esteroide
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8968755B2 (en) 2010-10-23 2015-03-03 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
US8809307B2 (en) * 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
CN103533926A (zh) * 2011-01-24 2014-01-22 安特里奥公司 空纳米颗粒组合物及其用于治疗皮肤病学病症的用途
GB201110632D0 (en) * 2011-06-22 2011-08-03 King S College London Drug delivery formulations
WO2013029009A1 (en) 2011-08-24 2013-02-28 Novan, Inc. Tunable nitric oxide-releasing macromolecules having multiple nitric oxide donor structures
US10111956B2 (en) 2013-06-03 2018-10-30 Tolmar, Inc. Corticosteroid compositions
KR102321169B1 (ko) 2013-08-08 2021-11-02 노반, 인크. 국소 조성물 및 그의 사용 방법
CN105682635A (zh) * 2013-08-09 2016-06-15 得凯莫斯公司弗罗里达有限公司 含有环状二酯的护肤组合物及其方法
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
CN108282998B (zh) 2015-06-18 2021-07-06 凡利亚药品北美公司 用于治疗银屑病的包含皮质类固醇和类视黄醇的局部组合物
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
EP3143986A1 (en) 2015-09-21 2017-03-22 Zimmer MedizinSysteme GmbH Hydrophilic gel for topical delivery of 5-aminolevulinic acid and production thereof
MX377365B (es) 2016-09-08 2025-03-10 Journey Medical Corp Composiciones y métodos para tratar rosácea y acné.
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US11311482B2 (en) 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
CN112566623A (zh) * 2018-08-16 2021-03-26 瑞迪博士实验室有限公司 局部用油质组合物
EP3930808A4 (en) * 2019-02-27 2022-12-14 Oticara, Inc. METHODS OF TREATMENT OF NASAL, SINONASAL AND NASOPHARYNGEAL TISSUE INFECTION AND/OR INFLAMMATION

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3592930A (en) * 1968-07-19 1971-07-13 Syntex Corp Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle
US4017615A (en) 1970-10-29 1977-04-12 Syntex Corporation Propylene carbonate ointment vehicle
US3934013A (en) * 1975-02-21 1976-01-20 Syntex (U.S.A.) Inc. Pharmaceutical composition
DE2964471D1 (en) * 1979-06-08 1983-02-17 Toko Yakuhin Kogyo Kk Creamy preparation containing steroid and process for the preparation thereof
JPS58225009A (ja) 1982-06-23 1983-12-27 Shionogi & Co Ltd コルチコステロイド外用製剤
JPS6136219A (ja) * 1984-07-27 1986-02-20 Shiseido Co Ltd 皮膚外用剤
US4879119A (en) * 1984-02-21 1989-11-07 Yamanouchi Pharmaceutical Co., Ltd. Patch
US4831023A (en) 1986-06-27 1989-05-16 Thames Pharmacal Co., Inc. Water washable vehicles for topical use
JPH0676328B2 (ja) * 1987-04-14 1994-09-28 株式会社大塚製薬工場 ステロイドクリ−ム製剤
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
WO1991008733A1 (en) * 1989-12-20 1991-06-27 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
WO1994012146A1 (en) * 1992-11-23 1994-06-09 Estee Lauder, Inc. Self-tanning cosmetic compositions and methods of using the same
US6300326B1 (en) 1994-11-02 2001-10-09 Michael R. Dobbs Composition and method for control and treatment of cutaneous inflammation
KR970064620A (ko) * 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
JPH10204001A (ja) * 1996-11-15 1998-08-04 Kao Corp 経皮吸収促進剤
US6075056A (en) 1997-10-03 2000-06-13 Penederm, Inc. Antifungal/steroid topical compositions
JPH11158060A (ja) * 1997-11-18 1999-06-15 Bristol Myers Squibb Co 長期間貯蔵される組成物中の医薬及び／又は透過増強剤が不安定なときに透過増強剤により医薬の皮膚透過を増強させる方法及び組成物
US6066281A (en) * 1998-06-16 2000-05-23 Velcro Industries B.V. Fastener products and their production
WO2000040250A1 (fr) * 1999-01-06 2000-07-13 Taisho Pharmaceutical Co.,Ltd. Lotion a base d'amelometasone
US6656928B1 (en) * 1999-09-02 2003-12-02 Mccadden Michael E. Composition for the topical treatment of rashes, dermatoses and lesions
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
US20050192261A1 (en) * 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102988992A (zh) * 2011-09-13 2013-03-27 日东电工株式会社 用于增强酸性药物的透皮吸收的组合物和贴片制剂
CN104884043A (zh) * 2012-10-18 2015-09-02 米卡尔制药有限公司-H系列 局部类固醇组合物和方法
CN104884043B (zh) * 2012-10-18 2018-12-11 米卡尔制药有限公司-H系列 局部类固醇组合物和方法

Also Published As

Publication number Publication date
WO2003055445A2 (en) 2003-07-10
US6765001B2 (en) 2004-07-20
MXPA04006014A (es) 2005-07-13
JP2005524614A (ja) 2005-08-18
CA2471041C (en) 2012-07-03
US20030176408A1 (en) 2003-09-18
US20030130247A1 (en) 2003-07-10
EP1465636A2 (en) 2004-10-13
US20030186951A1 (en) 2003-10-02
US7771733B2 (en) 2010-08-10
US20070142343A1 (en) 2007-06-21
US8232264B2 (en) 2012-07-31
CA2471041A1 (en) 2003-07-10
US7220424B2 (en) 2007-05-22
US7217422B2 (en) 2007-05-15
EP2363150A1 (en) 2011-09-07
US20100210615A2 (en) 2010-08-19
US20120289490A1 (en) 2012-11-15
WO2003055445A3 (en) 2003-10-09
AU2002360589A1 (en) 2003-07-15
BR0215254A (pt) 2005-02-01
US7794738B2 (en) 2010-09-14
AU2002360589B2 (en) 2007-03-15
US20090176750A1 (en) 2009-07-09
IL162581A0 (en) 2005-11-20
US20070142344A1 (en) 2007-06-21
US20100210609A2 (en) 2010-08-19
US20100210614A2 (en) 2010-08-19
EP1465636A4 (en) 2006-04-05
US20040198709A1 (en) 2004-10-07
JP2010280689A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
CN1617730A (zh) 用于增强皮质类固醇传递的组合物和方法
US11179465B2 (en) Topical compositions comprising a corticosteroid
CN101340916A (zh) 类固醇的经时稳定性得到改善的外用制剂
EP3003272A1 (en) Corticosteroid compositions
JP3029964B2 (ja) ステロイド類溶解剤及びステロイド類を主剤とする外用液剤
AU2002360589B9 (en) Compositions and methods for enhancing corticosteriod delivery
EP2004198A2 (en) Method of treating pediatric patients with corticosteroids

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication